SynthesisDeutsches Arzteblatt international2020
Hormonal Gender Reassignment Treatment for Gender Dysphoria.
Synthesis in Deutsches Arzteblatt international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05775328 (Gender Affirmative Treatment of Hypertrichosis With Intense Pulsed Light - Effect on Hair Reduction and Quality of Life), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Gender Affirmative Treatment of Hypertrichosis With Intense Pulsed Light - Effect on Hair Reduction and Quality of Life
Who cites it
13 citing papers in PubMed.
- [Gender-affirming hormone therapy: state of the art].Urologie (Heidelberg, Germany) · 2026Review
- Spatially resolved micromechanical characterisation of human testis tissue reveals distinct signatures across developing, adult and pathological tissue states.Bioactive materials · 2026Article
- Establishing a Transgender Outpatient Clinic Within the Gynaecology Department: a Retrospective Analysis of the First Few Years.Geburtshilfe und Frauenheilkunde · 2026Article
- Mental health implications of gender affirming care: bridging the communication and supportive gap.Annals of medicine and surgery (2012) · 2026Review
- Male Rat Model of Chemical Androgen Deprivation and Estrogenization from the Perspective of Anthropometric, Histological, and Biochemical Parameters.Medicina (Kaunas, Lithuania) · 2025Article
- Assessment of the care experience during medical transition for transgender and gender diverse people in France: results from the PREMIUM study.BMC public health · 2025Article
- Gender-affirming hormone therapy, quality of life, and the role of oestradiol and testosterone in transgender individuals.Acta neuropsychiatrica · 2025Article
- Metabolic Features of Assigned Female at Birth Transgender People on Gender-Affirming Hormone Therapy: A Meta-analysis.Transgender health · 2024Review
- Atypical Orthognathic Surgical Protocol for Facial Feminisation as an Adjunct to Gender Affirmation Therapy: a Case Report.Journal of maxillofacial and oral surgery · 2022Article
- Restriction of Access to Healthcare and Discrimination of Individuals of Sexual and Gender Minority: An Analysis of Judgments of the European Court of Human Rights from an Ethical Perspective.International journal of environmental research and public health · 2022Article
- Gender Dysphoria and Its Non-Surgical and Surgical Treatments.Health psychology research · 2022Article
- Acceptance, Use, and Barriers of Telemedicine in Transgender Health Care in Times of SARS-CoV-2: Nationwide Cross-sectional Survey.JMIR public health and surveillance · 2021Article
- Sex hormones drive changes in lipoprotein metabolism.iScience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNo data are available at present on the prevalence of gender dysphoria (trans-identity) in Germany. On the basis of estimates from the Netherlands, it can be calculated that approximately 15 000 to 25 000 persons in Germany are affected. Persons suffering from gender dysphoria often experience significant distress and have a strong desire for gender reassignment treatment.
methodsThis review is based on pertinent publications retrieved by a selective search in the PubMed database employing the searching terms "transsexualism," "transgender," "gender incongruence," "gender identity disorder," "gender-affirming hormone therapy," and "gender dysphoria."
resultsIn view of its far-reaching consequences, some of which are irreversible, hormonal gender reassignment treatment should only be initiated after meticulous individual consideration, with the approval of the treating psychiatrist/psychotherapist and after extensive information of the patient by an experienced endo - crinologist. Before the treatment is begun, the patient must be extensively screened for risk factors. The contraindications include severe preexisting thromboembolic diseases (mainly if untreated), hormone-sensitive tumors, and uncontrolled pre - existing chronic diseases such as arterial hypertension and epilepsy. Finding an appropriate individual solution is the main objective even if contraindications are present. Male-to-female treatment is carried out with 17β-estradiol or 17β-estradiol valerate in combination with cyproterone acetate or spironolactone as an antiandrogen, female-to-male treatment with transdermal or intramuscular testosterone preparations. The treatment must be monitored permanently with clinical and laboratory follow-up as well as with gynecological and urological early-detection screening studies. Prospective studies and a meta-analysis (based on low-level evidence) have documented an improvement in the quality of life after gender reassignment treatment. Female-to-male gender-incongruent persons often have difficulty being accepted in a gynecological practice as a male patient. CONCLUZION: Further prospective studies for the quantification of the risks and benefits of hormonal treatment would be desirable. Potential interactions of the hormone preparations with other medications must always be considered.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.